Compare Stocks: APVO, GTBP, ANEB, and AEON

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AEON AEON Biopharma	$0.26 -0.1%	$0.26	$0.18 ▼ $1.45	$12.92M	0.65	2.33 million shs	185,497 shs
ANEB Anebulo Pharmaceuticals	$0.30 -7.7%	$0.33	$0.00 ▼ $2.85	$12.24M	-1.82	28,896 shs	197 shs
APVO Aptevo Therapeutics	$1.88 +2.5%	$2.97	$1.37 ▼ $35.64	$3.39M	1.6	107,517 shs	8,538 shs
GTBP GT Biopharma	$6.78 -0.8%	$7.56	$4.91 ▼ $34.25	$12.19M	0.91	53,827 shs	47,410 shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AEON AEON Biopharma	-1.40%	+5.64%	+22.79%	-63.96%	-66.64%
ANEB Anebulo Pharmaceuticals	+8.33%	-2.75%	-1.52%	-17.72%	-86.73%
APVO Aptevo Therapeutics	-3.17%	-0.54%	-25.61%	-59.78%	-94.29%
GTBP GT Biopharma	-3.80%	-8.81%	-8.84%	-35.87%	-65.85%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AEON AEON Biopharma	$0.26 -0.1%	$0.26	$0.18 ▼ $1.45	$12.92M	0.65	2.33 million shs	185,497 shs
ANEB Anebulo Pharmaceuticals	$0.30 -7.7%	$0.33	$0.00 ▼ $2.85	$12.24M	-1.82	28,896 shs	197 shs
APVO Aptevo Therapeutics	$1.88 +2.5%	$2.97	$1.37 ▼ $35.64	$3.39M	1.6	107,517 shs	8,538 shs
GTBP GT Biopharma	$6.78 -0.8%	$7.56	$4.91 ▼ $34.25	$12.19M	0.91	53,827 shs	47,410 shs

The Best Nuclear Energy Stocks to Buy

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AEON AEON Biopharma	-1.40%	+5.64%	+22.79%	-63.96%	-66.64%
ANEB Anebulo Pharmaceuticals	+8.33%	-2.75%	-1.52%	-17.72%	-86.73%
APVO Aptevo Therapeutics	-3.17%	-0.54%	-25.61%	-59.78%	-94.29%
GTBP GT Biopharma	-3.80%	-8.81%	-8.84%	-35.87%	-65.85%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AEON AEON Biopharma	2.80	Moderate Buy	$1.33	412.82% Upside
ANEB Anebulo Pharmaceuticals	1.00	Sell	N/A	N/A
APVO Aptevo Therapeutics	1.00	Sell	N/A	N/A
GTBP GT Biopharma	1.00	Sell	N/A	N/A

Current Analyst Ratings Breakdown

Latest APVO, GTBP, ANEB, and AEON Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/10/2026	APVO Aptevo Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E) ➝ Sell (E+)
9/9/2026	AEON AEON Biopharma	Laidlaw Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$1.80
8/14/2026	AEON AEON Biopharma	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$5.00 ➝ $1.20
8/13/2026	APVO Aptevo Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (E+) ➝ Sell (E)
7/30/2026	AEON AEON Biopharma	Lake Street Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$1.00
7/29/2026	APVO Aptevo Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E) ➝ Sell (E+)
7/8/2026	GTBP GT Biopharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/1/2026	APVO Aptevo Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (E+) ➝ Sell (E)

(Data available from 9/25/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AEON AEON Biopharma	N/A	N/A	N/A	N/A	($4.12) per share	N/A
ANEB Anebulo Pharmaceuticals	N/A	N/A	N/A	N/A	$0.28 per share	N/A
APVO Aptevo Therapeutics	N/A	N/A	N/A	N/A	$17.42 per share	N/A
GTBP GT Biopharma	N/A	N/A	$0.35 per share	19.20	$5.66 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AEON AEON Biopharma	-$36.63M	-$4.42	1.44	N/A	N/A	N/A	N/A	-994.63%	11/13/2026 (Estimated)
ANEB Anebulo Pharmaceuticals	-$8.48M	-$0.19	N/A	N/A	N/A	N/A	-74.57%	-68.96%	9/25/2026 (Estimated)
APVO Aptevo Therapeutics	-$25.97M	-$51.83	N/A	N/A	N/A	N/A	-201.49%	-119.21%	11/5/2026 (Estimated)
GTBP GT Biopharma	-$28.35M	-$147.50	N/A	N/A	N/A	N/A	-213.16%	-150.61%	11/13/2026 (Estimated)

Latest APVO, GTBP, ANEB, and AEON Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
9/25/2026	Q4 2026	ANEB Anebulo Pharmaceuticals	-$0.10	N/A	N/A	N/A	N/A	N/A
8/14/2026	Q2 2026	APVO Aptevo Therapeutics	-$6.0150	-$5.31	+$0.7050	-$5.31	N/A	N/A
8/14/2026	Q2 2026	GTBP GT Biopharma	-$0.08	-$0.12	-$0.04	-$3.00	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AEON AEON Biopharma	N/A	N/A	N/A	N/A	N/A
ANEB Anebulo Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
APVO Aptevo Therapeutics	N/A	N/A	N/A	N/A	N/A
GTBP GT Biopharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AEON AEON Biopharma	N/A	0.22	0.22
ANEB Anebulo Pharmaceuticals	N/A	6.24	6.24
APVO Aptevo Therapeutics	N/A	2.08	2.08
GTBP GT Biopharma	N/A	2.61	2.61

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AEON AEON Biopharma	22.78%
ANEB Anebulo Pharmaceuticals	28.40%
APVO Aptevo Therapeutics	8.06%
GTBP GT Biopharma	8.15%

Insider Ownership

Company	Insider Ownership
AEON AEON Biopharma	9.40%
ANEB Anebulo Pharmaceuticals	80.60%
APVO Aptevo Therapeutics	0.37%
GTBP GT Biopharma	1.18%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AEON AEON Biopharma	8	49.88 million	74.37 million	Not Optionable
ANEB Anebulo Pharmaceuticals	4	40.79 million	7.91 million	Not Optionable
APVO Aptevo Therapeutics	33	1.81 million	1.80 million	Not Optionable
GTBP GT Biopharma	8	1.80 million	1.78 million	No Data

APVO, GTBP, ANEB, and AEON Headlines

Recent News About These Companies

GT Biopharma Expands Series M Preferred Financing Agreement

September 21, 2026 | tipranks.com

GT Biopharma consensus price target raised 2,400% to $76.50

September 15, 2026 | msn.com

GT Biopharma's GTB-5550 Secures FDA IND Clearance For Multiple Myeloma; Stock Down

September 15, 2026 | rttnews.com

GT Biopharma Announces FDA Clearance of IND for GTB-5550 in Multiple Myeloma and Updates on Phase 1 Trials

September 15, 2026 | quiverquant.comQ

GT Biopharma Announces Potential New Indication for GTB-5550, a B7-H3-Targeted Natural Killer (NK) Cell Engager, for Multiple Myeloma

September 15, 2026 | globenewswire.com

GT Biopharma, Inc. (GTBP) Discusses TriKE Platform, Clinical Progress, and the Case for NK Cell Immunotherapy Transcript

September 11, 2026 | seekingalpha.com

GT Biopharma Pops Ahead of Presentation

September 11, 2026 | baystreet.ca

GT Biopharma to Host Live Company Presentation on the Development of TriKE® Platform for Cancer Treatment, September 11, 2026

September 11, 2026 | globenewswire.com

GTBP stock holds steady as GT Biopharma advances TriKE cancer pipeline

August 29, 2026 | ad-hoc-news.deA

GT Biopharma (GTBP) Gets a Buy from Roth MKM

August 20, 2026 | theglobeandmail.com

GT Biopharma Shareholders Approve Reverse Split and Incentive Plan

August 14, 2026 | tipranks.com

GT Biopharma Reports Second Quarter 2026 Financial Results

August 14, 2026 | globenewswire.com

GT Biopharma (GTBP) Ratios

August 9, 2026 | uk.investing.com

A Clinical-Stage Cancer Company Is Putting AI to Work at the Bench, Designing Its Next Generation of Tumor-Targeting Drugs

July 6, 2026 | tmcnet.com

A Clinical-Stage Cancer Company Is Putting AI to Work Designing Its Next Generation of Tumor-Targeting Drugs

July 1, 2026 | theglobeandmail.com

A Third Cancer Drug Just Entered the Clinic at an Under-$20-Million Company

June 23, 2026 | theglobeandmail.com

After CAR-T, the Next Frontier in Cancer Immunotherapy May Belong to a Different Immune Cell

June 12, 2026 | financialpost.comF

Three Cancer Drugs Have Reached the Clinic: Inside GT Biopharma's TriKE Bet

June 8, 2026 | markets.businessinsider.com

Three Cancer Drugs Have Reached the Clinic: Inside GT Biopharma’s TriKE Bet

June 8, 2026 | financialpost.comF

GT Biopharma Provides Update on Pipeline Discovery Activities from Newly Implemented AI-Based Technological Initiatives

June 1, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

APVO, GTBP, ANEB, and AEON Company Descriptions

AEON Biopharma NASDAQ:AEON

$0.26 0.00 (-0.08%)

As of 12:02 PM Eastern

AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of both chronic and episodic migraine, as well as develops ABP-450 for the treatment of gastroparesis and posttraumatic stress disorder. The company is based in Irvine, California.

Anebulo Pharmaceuticals NASDAQ:ANEB

$0.30 -0.03 (-7.69%)

As of 09:37 AM Eastern

Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. The company's lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, which is in a Phase II clinical trial to address the unmet medical need for a specific antidote for ACI. Anebulo Pharmaceuticals, Inc. was incorporated in 2020 and is based in Lakeway, Texas.

Aptevo Therapeutics NASDAQ:APVO

$1.88 +0.05 (+2.46%)

As of 12:01 PM Eastern

Aptevo Therapeutics Inc., a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. It develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells. The company's lead clinical blood cancer candidate is APVO436 that is in Phase 1b/2 clinical trial for acute myelogenous leukemia. It is also developing ALG.APV-527, a novel investigational bispecific ADAPTIR candidate that is in Phase 1 clinical trial for NSCLC, head and neck, colorectal, pancreatic, breast, and other solid tumors; APVO603, a preclinical dual agonist bispecific ADAPTIR candidate for multiple solid tumors; APVO442, a novel bispecific candidate based on the ADAPTIR-FLEX platform technology for multiple solid tumors; and APVO711, a preclinical dual mechanism bispecific ADAPTIR candidate for prostate cancer. The company has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.

GT Biopharma NASDAQ:GTBP

$6.78 -0.06 (-0.81%)

As of 12:02 PM Eastern

GT Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate that is in Phase I clinical trial for the treatment of myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanced systemic mastocytosis, and CD33+ malignancies. The company is developing GTB-3650, which is in preclinical studies that target CD33 on the surface of myeloid leukemias; and GTB-5550 that is in preclinical studies for treating patients with B7-H3 positive solid tumors. GT Biopharma, Inc. has a co-development partnership agreement with Altor BioScience Corporation for the clinical development of a 161533 (GTB-3550) TriKE fusion protein for cancer therapies; and a license agreement with the Regents of the University of Minnesota to develop and commercialize cancer therapies using TriKE technology. The company was formerly known as OXIS International, Inc. and changed its name to GT Biopharma, Inc. in July 2017. GT Biopharma, Inc. was incorporated in 1965 and is based in Brisbane, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest APVO, GTBP, ANEB, and AEON Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest APVO, GTBP, ANEB, and AEON Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

APVO, GTBP, ANEB, and AEON Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

APVO, GTBP, ANEB, and AEON Company Descriptions

AEON Biopharma NASDAQ:AEON

Anebulo Pharmaceuticals NASDAQ:ANEB

Aptevo Therapeutics NASDAQ:APVO

GT Biopharma NASDAQ:GTBP

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest APVO, GTBP, ANEB, and AEON Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest APVO, GTBP, ANEB, and AEON Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

APVO, GTBP, ANEB, and AEON Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

APVO, GTBP, ANEB, and AEON Company Descriptions

AEON Biopharma NASDAQ:AEON

Anebulo Pharmaceuticals NASDAQ:ANEB

Aptevo Therapeutics NASDAQ:APVO

GT Biopharma NASDAQ:GTBP

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools